Tested Applications
| Positive WB detected in | A431 cells, HaCaT cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
11787-1-AP targets MPZL2 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag2419 Product name: Recombinant human MPZL2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-215 aa of BC017774 Sequence: MYGKSSTRAVLLLLGIQLTALWPIAAVEIYTSRVLEAVNGTDARLKCTFSSFAPVGDALTVTWNFRPLDGGPEQFVFYYHIDPFQPMSGRFKDRVSWDGNPERYDASILLWKLQFDDNGTYTCQVKNPPDVDGVIGEIRLSVVHTVRFSEIHFLALAIGSACALMIIIVIVVVLFQHYRKKRWAERAHKVVEIKSKEEERLNQEKKVSVYLEDTD Predict reactive species |
| Full Name | myelin protein zero-like 2 |
| Calculated Molecular Weight | 215 aa, 24 kDa |
| Observed Molecular Weight | 24-30 kDa |
| GenBank Accession Number | BC017774 |
| Gene Symbol | MPZL2 |
| Gene ID (NCBI) | 10205 |
| RRID | AB_2282054 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O60487 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
MPZL2 (myelin protein zero-like 2), also named as EVA (epithelial V-like antigen) or EVA1, is a type 1 transmembrane protein of the myelin P0 protein family, containing an Ig-like V-type (immunoglobulin-like) domain and two potential glycosylation sites. MPZL2 is expressed in thymus epithelium and strongly downregulated by thymocyte developmental progression. Its capacity to mediate cell adhesion through a homophilic interaction and its selective regulation by T cell maturation might imply the participation of EVA in the earliest phases of thymus organogenesis.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for MPZL2 antibody 11787-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The MPZL2 Polyclonal antibody (Cat# 11787-1-AP) has 14 total citations published across 13 journals, including Cell, Nature Communications, Journal of Immunotherapy of Cancer, Molecular Therapy, American Journal of Human Genetics, PLoS Pathogens, Cancer Science, Human Genetics, PLoS ONE, International Journal of General Medicine, Neuroscience Letters, Cells, and Journal of Translational Medicine. Research fields span hearing loss gene therapy, adipocyte biology, CAR-T cell development, glioblastoma, hepatocellular carcinoma, multiple sclerosis, thyroid cancer, and CNS immune surveillance.
| Species | Application | Title |
|---|---|---|
Nat Commun PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation | ||
J Immunother Cancer Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells | ||
Mol Ther Gene supplementation with precise transgene expression rescues hearing loss in a mouse model with an Mpzl2 East Asian founder variant. | ||
J Transl Med A small‑molecule HDAC/PDE modulator activates human adipocyte UCP1 and resolves inflammatory signaling. | ||
Am J Hum Genet Hearing restoration by gene replacement therapy for a multisite-expressed gene in a mouse model of human DFNB111 deafness
|
